Results 141 to 150 of about 2,002,341 (191)

Modeling the Synergistic Impact of Yttrium 90 Radioembolization and Immune Checkpoint Inhibitors on Hepatocellular Carcinoma. [PDF]

Bioengineering (Basel)
Kang M, Shin Y, Kim Y, Ha S, Sung W.
europepmc   +1 more source

Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization. [PDF]

Case Rep Oncol
Afghan MK, Lutfi A, Qadri F, Khan S, Javaid S, Currie BM, Rocca JP, Samstein B, Hissong E, Kasi PM.   +9 more
europepmc   +1 more source

Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition. [PDF]

J Hepatocell Carcinoma
Lüdemann WM, Kahn J, Herzler P, Collettini F, Savic LJ, Mohr R, Fehrenbach U, Auer TA, Gebauer B, Amthauer H, Wieners G.   +10 more
europepmc   +1 more source

Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging. [PDF]

Eur J Nucl Med Mol Imaging
Zeimpekis KG, Sari H, Gözlügöl N, Achangwa NR, Shi K, Schindewolf M, Afshar-Oromieh A, Rominger A, Seifert R.   +8 more
europepmc   +1 more source

Implications of lung shunt fraction calculation discrepancy in Yttrium-90 radioembolization treatment from 2D planar vs 3D single photon emission CT imaging. [PDF]

BJR Case Rep
Gamero Kubota P, Molvar C, Wagner R, Allam E, Halama J, James JR.   +5 more
europepmc   +1 more source

Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review. [PDF]

Clin Transl Oncol
González-Flores E, Zambudio N, Pardo-Moreno P, Gonzalez-Astorga B, de la Rúa JR, Triviño-Ibáñez EM, Navarro P, Espinoza-Cámac N, Casado MÁ, Rodríguez-Fernández A.   +9 more
europepmc   +1 more source

Quantitative evaluation of ⁹⁰Y-PET/CT and ⁹⁰Y-SPECT/CT-based dosimetry following Yttrium-90 radioembolization. [PDF]

Med Phys
Kappadath SC, Henry EC, Lopez BP, Mahvash A.   +3 more
europepmc   +1 more source

Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study. [PDF]

Br J Radiol
Topcuoglu OM, Orhan T, Gormez A, Alan N.
europepmc   +1 more source

Liver abscess following radioembolization with yttrium-90 microspheres

Wiener Klinische Wochenschrift, 2014
Radioembolization with yttrium-90 microspheres is an accepted and useful intervention model with minimal invasion in both primary and secondary liver malignancies. Radioembolization may lead to some complications. Liver abscess is a rare complication that can occur several weeks after radioembolization treatment of liver tumor with yttrium-90 ...
Mehmet Korkmaz, Mustafa Parildar, Celâl Çınar   +2 more
exaly   +8 more sources

History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma [PDF]

Journal of Clinical Medicine, 2019
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization since the 1960s.
Alex Wallace, Hassan Albadawi, Sadeer Alzubaidi   +2 more
exaly   +4 more sources